Poster Presentation (1107P): BRAF mutations and fusions in a real-world cohort of non-small cell lung cancer patients.Ultimately, this study found that the genomic landscape of non-smokers with small cell lung cancer significantly differs from that of smokers with small cell lung cancer. It was determined that "never smoking" patients were more likely to harbor mutations in oncogenic drivers (e.g., EGFR and PIK3CA) and exhibited lower tumor mutational burden (TMB) and immune cell infiltration than "current/former smoking" patients. Overview: Tempus conducted a retrospective analysis of de-identified records from small cell lung cancer patients who reported "never smoking" or "current/former smoking" status who underwent comprehensive genomic profiling with the Tempus xT assay.Location: 7.3.O, Orléans Auditorium, Paris Expo Porte de Versailles.Session Date & Time: September 12, 2022.Oral Discussion (1529MO): The genomic landscape of small cell lung cancer in never smoking patients.In a study of 289 patients, 81% of patients with CUP would have their treatment informed by TO tumor classification, ultimately expanding the treatment options for CUP patients. Overview: In this retrospective study, Tempus' Tumor Origin (TO) AI-driven algorithmic test – which uses tumor RNA expression results to predict the patient's most likely cancer type from 68 possible diagnoses – was shown to provide meaningful data that would have affected physicians' treatment decision-making for patients with cancer of unknown primary (CUP).Location: Poster Area, Hall 4, Paris Expo Porte de Versailles.Session Date & Time: September 11, 2022. Poster Presentation (923P): Molecular classification of cancers of unknown primary expands and refines treatment options.
0 Comments
Leave a Reply. |